Sutro Biopharma (STRO)

Sutro uses this platform to create antibody-drug conjugates and other biologic drug candidates intended to deliver potent therapies more selectively to diseased cells. Its pipeline has included STRO-002, also known as luveltamab tazevibulin, an antibody-drug conjugate directed at folate receptor alpha for ovarian and endometrial cancers. The company has also developed programs such as STRO-001 for hematologic malignancies and STRO-004, a tissue factor-targeted antibody-drug conjugate for solid tumors. Additional discovery and partnered programs include candidates referenced as STRO-006, STRO-00X, STRO-00Y, STRO-003, and vaccine-related programs such as VAX24 and VAX31 through collaborations.

A key part of Sutro’s strategy is to combine internal drug development with partnerships that apply its platform to external targets and therapeutic areas. This allows the company to pursue wholly owned assets while also generating potential collaboration revenue, milestones, and royalties. As a clinical-stage biopharma company, Sutro’s value is closely tied to trial data, regulatory progress, manufacturing execution, intellectual property protection, and its ability to translate platform advantages into differentiated medicines for patients with limited treatment options.